Mojca Lunder

716 total citations
41 papers, 553 citations indexed

About

Mojca Lunder is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Mojca Lunder has authored 41 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 16 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Surgery. Recurrent topics in Mojca Lunder's work include Diabetes Treatment and Management (12 papers), Cardiovascular Health and Disease Prevention (10 papers) and Lipoproteins and Cardiovascular Health (8 papers). Mojca Lunder is often cited by papers focused on Diabetes Treatment and Management (12 papers), Cardiovascular Health and Disease Prevention (10 papers) and Lipoproteins and Cardiovascular Health (8 papers). Mojca Lunder collaborates with scholars based in Slovenia, Italy and Romania. Mojca Lunder's co-authors include Miodrag Janić, Mišo Šabović, Andrej Janež, Gorazd Drevenšek, Borut Jug, Lovro Žiberna, Aleš Jerin, Srdjan Novaković, Darko Černe and Karin Kanc and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and European Journal of Pharmacology.

In The Last Decade

Mojca Lunder

38 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mojca Lunder Slovenia 14 292 169 137 99 79 41 553
Miodrag Janić Slovenia 14 315 1.1× 164 1.0× 135 1.0× 107 1.1× 93 1.2× 47 575
S. T. Turner United States 15 247 0.8× 156 0.9× 222 1.6× 68 0.7× 49 0.6× 18 626
Tomohiko Kanaoka Japan 17 345 1.2× 226 1.3× 119 0.9× 60 0.6× 142 1.8× 51 706
Sho Kinguchi Japan 15 155 0.5× 146 0.9× 88 0.6× 46 0.5× 113 1.4× 51 538
Chen Chi China 15 402 1.4× 202 1.2× 103 0.8× 134 1.4× 115 1.5× 49 753
Rosemarie Mellado Chile 13 217 0.7× 88 0.5× 118 0.9× 83 0.8× 196 2.5× 25 568
Takeshi Tobiume Japan 14 340 1.2× 80 0.5× 146 1.1× 39 0.4× 125 1.6× 38 585
Giovanni Cerasola Italy 15 370 1.3× 191 1.1× 77 0.6× 67 0.7× 85 1.1× 32 739
Douglas Greig Chile 12 226 0.8× 67 0.4× 71 0.5× 46 0.5× 64 0.8× 35 401
Noriko Ban Japan 17 568 1.9× 188 1.1× 282 2.1× 105 1.1× 113 1.4× 24 848

Countries citing papers authored by Mojca Lunder

Since Specialization
Citations

This map shows the geographic impact of Mojca Lunder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mojca Lunder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mojca Lunder more than expected).

Fields of papers citing papers by Mojca Lunder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mojca Lunder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mojca Lunder. The network helps show where Mojca Lunder may publish in the future.

Co-authorship network of co-authors of Mojca Lunder

This figure shows the co-authorship network connecting the top 25 collaborators of Mojca Lunder. A scholar is included among the top collaborators of Mojca Lunder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mojca Lunder. Mojca Lunder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Janić, Miodrag, Andrej Janež, Mišo Šabović, et al.. (2024). Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial. Journal of Clinical Medicine. 13(22). 6860–6860. 1 indexed citations
2.
Janić, Miodrag, Sabina Škrgat, Mojca Lunder, et al.. (2024). Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?. Medicina. 60(12). 2030–2030. 3 indexed citations
3.
Lunder, Mojca, et al.. (2023). Patterns of health enhancing physical activity in older patients with diabetes mellitus. Science & Sports. 39(2). 162–169. 1 indexed citations
4.
Lunder, Mojca, et al.. (2023). Effectiveness of a comprehensive telemedicine intervention replacing standard care in gestational diabetes: a randomized controlled trial. Acta Diabetologica. 60(8). 1037–1044. 11 indexed citations
5.
Lunder, Mojca, et al.. (2023). Health-Related Quality of Life Assessment in Older Patients with Type 1 and Type 2 Diabetes. Healthcare. 11(15). 2154–2154. 5 indexed citations
6.
Lunder, Mojca, et al.. (2018). The effect of micro-sized titanium dioxide on WM-266-4 metastatic melanoma cell line. Bosnian Journal of Basic Medical Sciences. 19(1). 60–66. 2 indexed citations
7.
Lunder, Mojca, et al.. (2018). Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovascular Diabetology. 17(1). 153–153. 78 indexed citations
8.
Janić, Miodrag, et al.. (2017). Metformin: from mechanisms of action to advanced clinical use. SHILAP Revista de lepidopterología. 1 indexed citations
9.
10.
Lunder, Mojca, et al.. (2017). Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus. Diabetes Research and Clinical Practice. 127. 181–186. 8 indexed citations
11.
12.
Janić, Miodrag, Mojca Lunder, & Mišo Šabović. (2015). A Low-Dose Combination of Fluvastatin and Valsartan: A New “Drug” and a New Approach for Decreasing the Arterial Age. BioMed Research International. 2015. 1–6. 12 indexed citations
13.
Janić, Miodrag, Mojca Lunder, Janja Zupan, et al.. (2014). The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig. European Journal of Pharmacology. 743. 31–36. 7 indexed citations
14.
Janić, Miodrag, Mojca Lunder, & Mišo Šabović. (2013). A new anti-ageing strategy focused on prevention of arterial ageing in the middle-aged population. Medical Hypotheses. 80(6). 837–840. 11 indexed citations
15.
Janić, Miodrag, et al.. (2013). A Combination of Low-Dose Fluvastatin and Valsartan Decreases Inflammation and Oxidative Stress in Apparently Healthy Middle-Aged Males. Journal of Cardiopulmonary Rehabilitation and Prevention. 34(3). 208–212. 18 indexed citations
16.
Lunder, Mojca, Miodrag Janić, Nataša Kejžar, & Mišo Šabović. (2012). Associations among different functional and structural arterial wall properties and their relations to traditional cardiovascular risk factors in healthy subjects: a cross-sectional study. BMC Cardiovascular Disorders. 12(1). 29–29. 15 indexed citations
17.
Lunder, Mojca, Lovro Žiberna, Gorazd Drevenšek, & Mišo Šabović. (2011). Beneficial Pleiotropic Effects of Statins. SHILAP Revista de lepidopterología. 1 indexed citations
18.
19.
Lunder, Mojca, Miodrag Janić, Borut Jug, & Mišo Šabović. (2011). The effects of low-dose fluvastatin and valsartan combination on arterial function: A randomized clinical trial. European Journal of Internal Medicine. 23(3). 261–266. 33 indexed citations
20.
Žiberna, Lovro, et al.. (2008). Normothermic and hypothermic models for studying the deleterious effects of hypoxia-reoxygenation on EDHF-mediated relaxation in isolated porcine coronary arteries. Journal of Pharmacological and Toxicological Methods. 59(1). 1–6. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miodrag Janić Breakdown of academic impact, for papers by S. T. Turner Breakdown of academic impact, for papers by Tomohiko Kanaoka Breakdown of academic impact, for papers by Sho Kinguchi Breakdown of academic impact, for papers by Chen Chi Breakdown of academic impact, for papers by Rosemarie Mellado Breakdown of academic impact, for papers by Takeshi Tobiume Breakdown of academic impact, for papers by Giovanni Cerasola Breakdown of academic impact, for papers by Douglas Greig Breakdown of academic impact, for papers by Noriko Ban
Rankless by CCL
2026